Cellular Senescence Network (SenNet):Technology Projects (UG3/UH3 Clinical Trial Not Allowed)
Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.
If you're building tools or platforms to measure or study cellular senescence, NIH is signaling dedicated funding—but you'll need a strong research plan and institutional backing.
Report stale or inaccurate summary
What this is
The Cellular Senescence Network (SenNet) is an NIH program funding technology projects to advance understanding and measurement of cellular senescence. This opportunity explicitly excludes UG3/UH3 clinical trial mechanisms, suggesting it targets bench research, computational tools, assays, and platforms. Researchers with biotech or healthcare tech innovations relevant to senescence detection, characterization, or intervention may find a fit, though the thin description requires checking the full RFP details.
Who can apply
Eligibility criteria not specified in provided text; applicant types and award ranges unknown. Standard NIH rules likely apply: U.S. institutions (academic, non-profit, small business) eligible. Check full RFP for specific eligibility and cost-share requirements. Clinical trial applications explicitly excluded.
Topics: cellular senescence · biotech research funding · nih sennet · aging biology · technology development
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.